Chai Discovery

chaidiscovery.com →

-51%

est. 2Y upside i

HealthcareSeries B

Chai has built an AI model that its founders claim can transform the process of designing molecules that bind to proteins and influence their function. The company aims to enable the creation of de novo antibodies and, ultimately, drugs.

Rank

#2122

Sector

AI Drug Discovery

Est. Liquidity

~4Y

Data Quality

Data: Medium

Chai Discovery operates in the high-growth AI drug discovery market, leveraging proprietary AI models that show a 100-fold improvement in antibody design success rates, validated by a recent collaboration with Eli Lilly.

Last updated: March 10, 2026

Bull (25%)+200%

Chai Discovery's proprietary Chai-2 AI models continue to deliver 100-fold improvements in antibody design, leading to multiple successful drug candidates entering clinical trials through partnerships beyond Eli Lilly. This drives significant market share capture in the rapidly expanding AI drug discovery market, pushing valuation to $3.9B (3x current) within two years.

Base (30%)+75%

Chai Discovery maintains its strong technological lead and expands collaborations, but faces sustained competition from incumbents and the inherent long timelines of drug development. The company achieves steady growth, reaching a valuation of approximately $2.275B (1.75x current) as its platform gains broader adoption in early-stage discovery.

Bear (45%)-60%

Well-funded incumbents like Isomorphic Labs or Google DeepMind launch directly competing platforms that erode Chai Discovery's market position, or regulatory hurdles and clinical trial failures by partners slow adoption. This leads to a down round or flat valuation, with the $230M liquidation preference significantly impacting common stock value, resulting in a valuation of $0.52B (0.4x current).

Est. time to liquidity~3.5 years

Preference Stack Risk

high

Funding Intensity

18%

Investors hold $230M in liquidation preferences, meaning common shareholders would only see returns after this amount is paid out in an exit.

Dilution Risk

moderate

As a Series B company, Chai Discovery will likely require at least one more significant funding round (Series C) before a liquidity event, posing future dilution risk.

Secondary Liquidity

limited

While private company valuation data is available, active secondary markets or tender offers for employees are not explicitly indicated.

Commercial — 3 roles

Engineering — 2 roles

Other — 2 roles

Research — 2 roles

Science — 2 roles

Product — 1 role

View all 12 open roles at Chai Discovery →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Chai Discovery's data — designed to show you've done your homework.

  • 1

    “Given the significant investments by large pharmaceutical companies and tech giants like Alphabet (Isomorphic Labs) in AI drug discovery, how does Chai Discovery plan to maintain its competitive edge and market position against such well-resourced incumbents?”

  • 2

    “The collaboration with Eli Lilly is a strong validation. How does Chai Discovery envision scaling these partnerships, and what are the key milestones for demonstrating the long-term value and clinical impact of your AI platform within these collaborations?”

  • 3

    “With $230M raised on a $1.3B valuation, what is the company's strategy for future funding rounds and eventual liquidity, particularly concerning potential dilution and ensuring meaningful returns for common shareholders?”

Community

Valuation Sentiment

Our model estimates -51% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.